REGENXBIO Inc. (RGNX) Financial Statements (2024 and earlier)

Company Profile

Business Address 9804 MEDICAL CENTER DRIVE
ROCKVILLE, MD 20850
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:565,200849,300522,500400,000470,600176,400
Cash and cash equivalents96,952345,209338,42669,51475,56146,656
Short-term investments267,690112,230137,314226,696244,200114,122
Other undisclosed cash, cash equivalents, and short-term investments200,558391,86146,760103,790150,83915,622
Receivables28,08232,43942,99938,1488,587473
Prepaid expense13,90018,75210,5056,4755,7345,334
Other current assets9,35210,1961,9534,1993,8311,412
Other undisclosed current assets(200,558)(391,861)(46,760)(103,790)(150,839)(15,622)
Total current assets:415,976518,826531,197345,032337,913167,997
Noncurrent Assets
Operating lease, right-of-use asset65,11660,90463,81510,078
Property, plant and equipment141,685131,54756,46728,97328,70213,977
Long-term investments and receivables202,064394,16950,076107,940173,83115,616
Long-term investments200,560391,90746,809103,785150,81915,616
Accounts and financing receivable, after allowance for credit loss1,5042,2623,2674,15523,012 
Restricted cash and investments2,0302,0301,3301,3301,053225
Other noncurrent assets6,3976,4285,2794,5552,315862
Total noncurrent assets:417,292595,078176,967152,876205,90130,680
TOTAL ASSETS:833,2681,113,904708,164497,908543,814198,677
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities46,03043,30527,08817,54114,69110,857
Taxes payable11,3253,135 726 
Employee-related liabilities19,84913,15510,9039,4845,789
Accounts payable27,21311,38710,6226,4094,4124,832
Accrued liabilities18,81774417622969236
Deferred revenue1,8293,333449 
Debt    2,421  
Contract with customer, liability600
Other undisclosed current liabilities82,57583,83453,91013,7146,8853,580
Total current liabilities:130,434130,47281,44733,67622,17614,437
Noncurrent Liabilities
Long-term debt and lease obligation:  84,92970,1538,874  
Liabilities, other than long-term debt97,6347454,3075,1616,9361,211
Deferred revenue and credits1,211
Deferred revenue   3,7833,333
Contract with customer, liability3,333
Deferred rent credit     1,098
Other liabilities8,8327455241,8282,505 
Operating lease, liability88,80284,92970,1538,874
Other undisclosed noncurrent liabilities89,005133,460174,504 5,854 
Total noncurrent liabilities:186,639219,134248,96414,03512,7901,211
Total liabilities:317,073349,606330,41147,71134,96615,648
Equity
Equity, attributable to parent516,195764,298377,753450,197508,848183,029
Common stock444443
Additional paid in capital973,145928,095667,181627,810592,580371,497
Accumulated other comprehensive income (loss)(15,401)(2,569)(360)205(720)(715)
Accumulated deficit(441,553)(161,232)(289,072)(177,822)(83,016)(187,756)
Total equity:516,195764,298377,753450,197508,848183,029
TOTAL LIABILITIES AND EQUITY:833,2681,113,904708,164497,908543,814198,677

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues112,724470,347154,56735,233218,50510,393
Revenue, net10,393
Cost of revenue(54,545)(51,833)(43,689)(8,241)(9,682)(1,825)
Cost of goods and services sold(54,545)(51,833)(35,714)(8,241) (1,709)
Gross profit:58,179418,514110,87826,992208,8238,568
Operating expenses(327,734)(260,770)(230,111)(176,000)(120,723)(84,453)
Other operating income (expense), net    10(42)(116)
Other undisclosed operating income 6,6792,236  42116
Operating income (loss):(262,876)159,980(119,233)(148,998)88,100(75,885)
Nonoperating income (expense)(17,529)(18,733)13,22351,51016,0162,716
Investment income, nonoperating5,3836,8259,72348,5597,0702,716
Interest and debt expense(23,254)(26,277)(771)   
Income (loss) from continuing operations before equity method investments, income taxes:(303,659)114,970(106,781)(97,488)104,116(73,169)
Other undisclosed income from continuing operations before income taxes23,25426,277771   
Income (loss) from continuing operations before income taxes:(280,405)141,247(106,010)(97,488)104,116(73,169)
Income tax expense (benefit)84(13,407)(5,240)2,755(4,179) 
Income (loss) from continuing operations:(280,321)127,840(111,250)(94,733)99,937(73,169)
Income (loss) before gain (loss) on sale of properties:127,840(111,250)(94,733)99,937(73,169)
Net income (loss) available to common stockholders, diluted:(280,321)127,840(111,250)(94,733)99,937(73,169)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(280,321)127,840(111,250)(94,733)99,937(73,169)
Other comprehensive income (loss)(12,832)(2,209)(565)885(5)(682)
Comprehensive income (loss), net of tax, attributable to parent:(293,153)125,631(111,815)(93,848)99,932(73,851)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: